ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interleukins (IL)"

  • Abstract Number: 2879 • 2014 ACR/ARHP Annual Meeting

    Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β-Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1 Activation in Human Rheumatoid Arthritis Synovial Fibroblasts

    Anil Singh1, Sharayah Riegsecker2, Sadiq Umar1 and Salahuddin Ahmed1, 1Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, 2Department of Pharmacology, University of Toledo, Toledo, OH

    Background/Purpose: In rheumatoid arthritis (RA), the role of interleukin-1β (IL-1β) signaling proteins (IRAK-1/TAK-1/TRAF-6) proximal to IL-1 receptor in mediating proinflammatory response is not completely understood.…
  • Abstract Number: 665 • 2014 ACR/ARHP Annual Meeting

    Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus

    Jing He1, Xia Zhang2, Xiaolin Sun3, Jianping Guo3, Yunbo Wei4, Zhaohua Hou4, Yu Di5 and Zhanguo Li3, 1Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China, 2Department of Rheumatology & immunology, Peking University People's Hospital, Beijing, China, 3Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 4Immunology for Environment and Health, Shandong Analysis and Test Center, Shandong Academy of Science, Shandong, China, 5Molecular Immunomodulation Laboratory, Monash University, Clayton, Austria

    Background/Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance to nuclear self-antigens, production of pathogenic autoantibodies and damage tomultiple organs.…
  • Abstract Number: 2837 • 2014 ACR/ARHP Annual Meeting

    Induction of Clinical Remission By Low-Dose Interleukin-2 in Refractory SLE

    Jens Y. Humrich1, Caroline von Spee-Mayer1, Elise Siegert1, Angelika Rose1, Tobias Alexander2, Falk Hiepe1, Andreas Radbruch3, Gerd Burmester4 and Gabriela Riemekasten1, 1Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, 3German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, 4Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany

    Background/Purpose Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
  • Abstract Number: 322 • 2014 ACR/ARHP Annual Meeting

    Superior Therapeutic Efficacy of a Novel Oral Small Molecule Retinoic Acid Receptor-Related Orphan Receptor Gamma T [Rorgt] Inverse Agonist Inv-17: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis

    Anderson Gaweco1,2, Samantha Palmer1, Rambon Shamilov1, Caroline Stremnitzer1, Katie Matthews1, Michael Fisher1, William Windsor1, James Blinn1, Ellen M. Ginzler3 and Jefferson Tilley1, 1Innovimmune Biotherapeutics, Brooklyn, NY, 2SUNY-Downstate Medical Center, Brooklyn, NY, 3Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY

    Background/Purpose: T helper 17 [TH17] cells and its production of TH17 cytokines IL-17A and IL-17F play a critical role in the pathogenesis of RA and…
  • Abstract Number: 2168 • 2014 ACR/ARHP Annual Meeting

    Extramedullary Myelopoiesis Drives Persistent Toll-like Receptor-Mediated Inflammation

    Lehn K. Weaver1 and Edward M. Behrens2, 1Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Many rheumatic diseases are driven by chronic, repeated activation of Toll-like receptors (TLR) causing the initiation and perpetuation of disease. However, TLR-activated innate immune…
  • Abstract Number: 311 • 2014 ACR/ARHP Annual Meeting

    Inhibition of Natural Killer (NK) Cell Cytotoxicity By Interleukin-6 (IL-6): Implications for the Pathogenesis of Macrophage Activation Syndrome

    Loredana Cifaldi1, Giusi Prencipe2, Ivan Caiello2, Claudia Bracaglia2, Raffaele Strippoli3 and Fabrizio De Benedetti Sr.2, 1Paediatric Haematology/Oncology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 2Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 3Cellular Biotechnologies and Haematology, Sapienza Rome University, Rome, Italy

    Background/Purpose: MAS occurs frequently in patients with active systemic juvenile idiopathic arthritis(s-JIA) and because of the similarities with Haemophagocytic Lymphohistiocytosis (HLH) is classified among secondary…
  • Abstract Number: 2039 • 2014 ACR/ARHP Annual Meeting

    Among Persons Assayed with Lower Serum Interleukin-1 Beta (IL-1β) Levels, Serum Androstenedione (Δ4A) and Testosterone (T) Were Significantly Lower in a Community-Based Cohort of Rheumatoid Arthritis Multi-Years before Clinical Onset (Pre-RA) Than in Non-RA Matched Control (CN) Subjects

    Alfonse T. Masi, Azeem A. Rehman and Jean C. Aldag, Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL

    Background/Purpose: Dysregulations in androgenic-anabolic (A-A) steroids and cytokines are recognized in RA and pre-RA subjects (Rheum Dis Clin N Am 2005; 31: 131-60). However, deviations…
  • Abstract Number: 81 • 2014 ACR/ARHP Annual Meeting

    Elevated Peripheral Blood Leukocyte Inflammatory Gene Expression in Radiographic Progressors with Symptomatic Knee Osteoarthritis: NYU and OAI Cohorts

    Mukundan Attur1, Alexander Statnikov2, Svetlana Krasnokutsky Samuels1, Virginia B. Kraus3, Joanne Jordan4, Braxton D. Mitchell5, Michelle Yau6, Jyoti Patel1, Constantin F. Aliferis2, Marc C. Hochberg7, Jonathan Samuels1 and Steven B. Abramson8, 1Rheumatology, NYU Langone Medical Center, New York, NY, 2Center for Health Informatics and Bioinformatics, NYU Langone Medical Center, New York, NY, 3Medicine/Rheumatology, Duke University Medical Center, Durham, NC, 4Thurston Arthritis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 5Departments of Medicine and Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD, 6Epidemiology and Public Health, University of Maryland, Baltimore,, MD, 7Medicine, University of Maryland School of Medicine, Baltimore, MD, 8Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY

    Background/Purpose: We and others have demonstrated low grade inflammation exists in OA joint tissues, where it may contribute to disease pathogenesis. In the current studies…
  • Abstract Number: 1816 • 2014 ACR/ARHP Annual Meeting

    Toll-like Receptor 4-Induced Interleukin-1 Defines the Intestinal Microbiome and Mucosal Immune Response in Arthritis-Prone IL-1 Receptor Antagonist Deficient Mice

    Tom Ederveen1, Rebecca Rogier2, Jos Boekhorst1, Harm Wopereis3, Johan Garssen3, Sacha van Hijum1, Fons A.J. van de Loo2, Marije I. Koenders2, Wim B. van den Berg2 and Shahla Abdollahi-Roodsaz4, 1Centre for Molecular Bioinformatics Nijmegen (CMBI), Radboud university medical center, Nijmegen, Netherlands, 2Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 3Danone Research, Wageningen, Netherlands, 4Rheumatology, Radboud university medical center, Nijmegen, Netherlands

    Background/Purpose Interleukin-1 (IL-1) plays a pivotal role in inflammation and autoimmunity. Mice deficient in the IL-1 receptor antagonist (IL-1Ra-/-) spontaneously develop a T cell-driven autoimmune…
  • Abstract Number: 1746 • 2014 ACR/ARHP Annual Meeting

    Involvement of IL-17-Producing MAIT Cells in the Pathogenesis of Rheumatoid Arthritis

    Eri Hayashi1, Asako Chiba2, Mie Kitagaichi3, Kurisu Tada3, Ken Yamaji4, Naoto Tamura1, Yoshinari Takasaki3 and Sachiko Miyake2, 1Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Immunology, Juntendo University School of Medicine, Tokyo, Japan, 3Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 4Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

    Background/Purpose: Mucosal-associated invariant T (MAIT) cells are a subset of innate-like lymphocytes which are restricted by the MHC-related molecule-1 (MR1) and express a semi-invariant TCRα…
  • Abstract Number: 1732 • 2014 ACR/ARHP Annual Meeting

    Attenuation of Sclerodermatous Graft Versus Host Disease (sclGVHD) in IL4RA Receptor-Deficient Mice

    Katia Urso1, Kelly Tsang2, Robert Lafyatis3 and Antonios O. Aliprantis2, 1Rheumatology, Brigham and Women's Hospital, Boston, MA, 2Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Rheumatology, Boston University School of Medicine, Boston, MA

    Background/Purpose Scleroderma is a rare autoimmune disease characterized by the accumulation of fibrotic tissue in multiple organs including the skin, gut and lungs. To date,…
  • Abstract Number: 931 • 2013 ACR/ARHP Annual Meeting

    Effect Of Neutralizing IL-17A and IL-17F Antibodies On Host Resistance To Acute Mycobacterium Tuberculosis Infection In Mice In Comparison With Neutralizing TNF-α Treatment

    Michael Kammüller1, Franco Di Padova2, Christian Antoni3, Salah-Dine Chibout4, Timothy Wright5, Marie-Laure Bourigault6, Noria Segueni6, Stephanie Rose6, Bernhard Ryffel6 and Valerie Quesniaux6, 1PCS - Discovery and Investigative Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland, 2Autoimmunity, Transplantation and Inflammation, Novartis Institutes for Biomedical Research, Basel, Switzerland, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4Novartis Institutes for Biomedical Research, Basel, Switzerland, 5Novartis Pharma AG, Basel, Switzerland, 6UMR7355 CNRS and University of Orleans, Orleans, France

    Background/Purpose: Antibodies targeting IL-17A or IL-17RA are in clinical trials for the treatment of several autoimmune diseases.  However, these therapies, by blocking critical mediators of…
  • Abstract Number: 940 • 2013 ACR/ARHP Annual Meeting

    Novel Function Of Soluble Interleukin-6 Receptor As An Antagonist Of Interleukin-27-Mediated Anti-Inflammatory Responses

    Misato Hashizume1, Keiko Esaki2, Keiko Yoshimoto3, Hideto Kameda3, Tsutomu Takeuchi3 and Yoshihiro Matsumoto1, 1Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 2Discovery Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 3Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: The immunological roles of interleukin 27 (IL-27) have been reported in various rheumatic diseases, such as rheumatoid arthritis (RA), lupus, systemic sclerosis and psoriasis.…
  • Abstract Number: 943 • 2013 ACR/ARHP Annual Meeting

    Synergism Between Granulocyte-Macrophage Colony Stimulating Factor and Interleukin-17 Causes Joint Damage Via The Production Of Interleukin-23, Receptor Activator Of NF-κB Ligand and S100A8

    Annemarie E.M. Van Nieuwenhuijze1, Fons A.J. Van de Loo2, Birgitte Walgreen3, Miranda B. Bennink4, Monique M. Helsen3, Liduine Van den Bersselaar1, Ian P. Wicks5,6, Wim B. Van den Berg7 and Marije I. Koenders7, 1Rheumatology and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Rheumatology Research and Advanced Therapeutics, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 3Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Inflammation Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, Australia, 6Department of Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, 7Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands

    Background/Purpose: T helper-17 (Th17) cells are important mediators of inflammatory diseases, and are the main pathogenic cell type in many animal models of autoimmunity. Recent…
  • Abstract Number: 2801 • 2013 ACR/ARHP Annual Meeting

    Comparative Longitudinal Analysis Of Periarticular Bone Structure In Patients Treated With Methotrexate In Combination Of Either TNF Blockers Or Tocilizumab

    Sebastian Kraus1, Matthias Englbrecht1, Juergen Rech2, Roland Kocijan1, Georg A. Schett1 and Stephanie Finzel1, 1Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Inhibition of tumor necrosis factor alpha (TNFi) and interleukin-6 receptor (IL6Ri, tocilzumab) are among the most potent therapeutic strategies in patients with rheumatoid arthritis…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology